

RSV Vaccine Quick Reference Guide for Immunizers

Disclaimer: this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information

AREXVY GlaxoSmithKline Inc.

Respiratory Syncytial Virus (RSV) Vaccine Recombinant, Adjuvanted

Product Monograph: <https://ca.gsk.com/media/xy1dtaaz/arexvy.pdf>

Presentation	Storage & Handling	Eligibility Criteria	Administration
<p>AREXVY is supplied in a 1-pack box Requires reconstitution</p> <p><u>Each box contains:</u></p> <ul style="list-style-type: none"> 1 dose of the lyophilized antigen (powder) in a type I glass, single-dose vial with a mustard-coloured vial cap and a butyl rubber stopper. 1 dose of the adjuvant (suspension) in a type I glass, single-dose vial with a brown vial cap and a butyl rubber stopper <p>AREXVY is supplied in 2 vials that must be combined prior to administration. Prepare AREXVY by reconstituting the lyophilized RSVPreF3 antigen (powder (mustard-coloured cap)) with the accompanying AS01E adjuvant suspension (liquid (brown cap)).</p> <p>The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid.</p>	<p>Storage: 2° to 8°C Do not freeze <i>Discard product if exposed to freezing</i></p> <p>Protect from light</p> <p><u>After reconstitution:</u> administer AREXVY promptly or store in the refrigerator (2°C – 8°C) or at room temperature up to 25°C for use within 4 hours. If not used within 4 hours, the reconstituted vaccine should be discarded.</p> <p><i>Product should be inspected visually for particulate matter and/or variation of appearance (e.g., discoloration) prior to administration. If either of these conditions exists, the vaccine should not be administered.</i></p>	<p>Individuals aged 60 years of age and older are eligible for one dose of the RSV vaccine if they:</p> <ul style="list-style-type: none"> Reside in a personal care home (PCH), or Have been admitted to a PCH for respite care, or Have been admitted to a transitional care unit AND have been paneled for PCH and are awaiting placement, or Have been admitted to a chronic care unit AND have been paneled for PCH. <p><i>It is recommended that personal care homes plan to administer the RSV vaccine minimum of two (2) weeks before the administration of influenza vaccines. However, the RSV vaccine may be administered at the same time as other vaccines on an individual resident basis.</i></p>	<p>Dose: 0.5ml</p> <p>Route: Intramuscular (IM) Deltoid</p> <p>Schedule: 1 dose <i>If previously immunized with a RSV vaccine, an additional dose is not recommended.</i></p> <p>Recommended Needle Gauge and Length: 22-25G 1" - 1 ½"</p>
<p>Medicinal ingredients: Respiratory Syncytial Virus PreF3 (RSVPreF3) glycoprotein F antigen, Quillaja saponaria Molina, fraction 21 (QS-21), 3-O-desacyl-4'-monophosphoryl lipid A (MPL)</p> <p>Non-medicinal ingredients: Cholesterol, dioleoyl phosphatidylcholine, dipotassium phosphate, disodium phosphate anhydrous, MPL2, polysorbate 80, potassium dihydrogen phosphate, QS-212, sodium chloride, trehalose dihydrate</p>			

RSV Vaccine Quick Reference Guide for Immunizers

Disclaimer: this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information

ABRYSVO™ Pfizer

Respiratory Syncytial Virus (RSV) Stabilized Prefusion F Subunit Vaccine

Product Monograph: [b3cae670-abaf-4567-94de-6c5997272d2b \(pfizer.com\)](https://www.pfizer.com/abrysvo)

Presentation	Storage & Handling	Eligibility Criteria	Administration
<p>Abrysvo™ is supplied as a carton containing 10 vials of powder, 10 pre-filled syringes of diluent and 10 vial adapters.</p> <p>Requires dilution with 0.65ml sterile water (supplied)</p> <p>The vaccine is a lyophilized white powder for solution provided in a single-dose vial that must be reconstituted with sterile water diluent before use.</p> <p>The final reconstituted solution is clear and colourless. Completely and slowly withdraw the entire contents into the syringe to ensure a 0.5 mL dose of Abrysvo™.</p>	<p>Storage: 2° to 8°C Do not freeze <i>Discard product if exposed to freezing</i></p> <p>Protect from light</p> <p>Use as soon as possible after removal from refrigeration</p> <p><u>After reconstitution:</u> Abrysvo™ should be administered immediately (within 4 hours) after reconstitution. Store the reconstituted vaccine between 15°C and 30°C.</p> <p>Do not use this vaccine after the expiry date (the expiry date refers to the last day of that month).</p>	<p>Individuals aged 60 years of age and older are eligible for one dose of the RSV vaccine if they:</p> <ul style="list-style-type: none"> Reside in a personal care home (PCH), or Have been admitted to a PCH for respite care, or Have been admitted to a transitional care unit AND have been paneled for PCH and are awaiting placement, or Have been admitted to a chronic care unit AND have been paneled for PCH. <p><i>It is recommended that personal care homes plan to administer the RSV vaccine minimum of two (2) weeks before the administration of influenza vaccines. However, the RSV vaccine may be administered at the same time as other vaccines on an individual resident basis.</i></p>	<p>Dose: 0.5ml</p> <p>Route: Intramuscular (IM) Deltoid</p> <p>Schedule: 1 dose <i>If previously immunized with a RSV vaccine, an additional dose is not recommended.</i></p> <p>Recommended Needle Gauge and Length: 22-25G 1" - 1 ½"</p>
<p>Medicinal ingredients: RSV prefusion F antigens (A and B)</p> <p>Non-medicinal ingredients: Mannitol, polysorbate 80, sodium chloride, sucrose, tromethamine, trometamol hydrochloride</p>			